Leroux-Roels, I.;                     Bruhwyler, J.;                     Stergiou, L.;                     Sumeray, M.;                     Joye, J.;                     Maes, C.;                     Lambert, P.-H.;                     Leroux-Roels, G.    
        Double-Blind, Placebo-Controlled, Dose-Escalating Study Evaluating the Safety and Immunogenicity of an Epitope-Specific Chemically Defined Nanoparticle RSV Vaccine. Vaccines 2023, 11, 367.
    https://doi.org/10.3390/vaccines11020367
    AMA Style
    
                                Leroux-Roels I,                                 Bruhwyler J,                                 Stergiou L,                                 Sumeray M,                                 Joye J,                                 Maes C,                                 Lambert P-H,                                 Leroux-Roels G.        
                Double-Blind, Placebo-Controlled, Dose-Escalating Study Evaluating the Safety and Immunogenicity of an Epitope-Specific Chemically Defined Nanoparticle RSV Vaccine. Vaccines. 2023; 11(2):367.
        https://doi.org/10.3390/vaccines11020367
    
    Chicago/Turabian Style
    
                                Leroux-Roels, Isabel,                                 Jacques Bruhwyler,                                 Lilli Stergiou,                                 Mark Sumeray,                                 Jasper Joye,                                 Cathy Maes,                                 Paul-Henri Lambert,                                 and Geert Leroux-Roels.        
                2023. "Double-Blind, Placebo-Controlled, Dose-Escalating Study Evaluating the Safety and Immunogenicity of an Epitope-Specific Chemically Defined Nanoparticle RSV Vaccine" Vaccines 11, no. 2: 367.
        https://doi.org/10.3390/vaccines11020367
    
    APA Style
    
                                Leroux-Roels, I.,                                 Bruhwyler, J.,                                 Stergiou, L.,                                 Sumeray, M.,                                 Joye, J.,                                 Maes, C.,                                 Lambert, P.-H.,                                 & Leroux-Roels, G.        
        
        (2023). Double-Blind, Placebo-Controlled, Dose-Escalating Study Evaluating the Safety and Immunogenicity of an Epitope-Specific Chemically Defined Nanoparticle RSV Vaccine. Vaccines, 11(2), 367.
        https://doi.org/10.3390/vaccines11020367